Luther Carter, MD
Interventional Cardiology · Pensacola, FLNPI 1710062732
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,555 of the $8,981 with a category attached, or 73.0%. 23 manufacturers reported payments, led by Abbott at 29.2% of the total. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 147 payments — averaging $61.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Abiomed$3K
- Edwards Lifesciences$2K
- Medtronic$718
- Boston Scientific$535
- Biotronik Inc.$107
- plus $760 from 17 others
Across 101 payments — averaging $2637.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$138K
- Amgen$129K
What the payments were for
- Travel & lodging$2,42527%
- Food & beverage$6,55573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $2,622 |
| Abiomed | 47 | $2,610 |
| Edwards Lifesciences | 8 | $1,626 |
| Medtronic(2 entities) | 12 | $718 |
| Boston Scientific | 17 | $535 |
| Biotronik Inc. | 1 | $107 |
| Celonova Biosciences, Inc. | 1 | $102 |
| Amgen | 6 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $89 |
| Pfizer | 4 | $64 |
| W. L. Gore & Associates, Inc. | 2 | $59 |
| Penumbra, Inc. | 3 | $56 |
| Philips North America LLC | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Stryker | 1 | $43 |
| GE HealthCare | 1 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Livanova USA, Inc. | 1 | $19 |
| Acist Medical Systems, Inc. | 1 | $19 |
| Elutia, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,770
- TRICLIP$1,676
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,194
- COREVALVE EVOLUT R$274
- Resolute$265
- Mitra Clip system$231
- GENERAL - STRUCTURAL HEART$226
- CardioMEMS HF System$117
- MitraClip$105
How this compares
$8,981 in reported general payments places this provider in the 50th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $32,363 |
| BrilintaTicagrelor | 30 | $22,900 |
| EntrestoSacubitril/Valsartan | 15 | $17,397 |
| ClopidogrelClopidogrel Bisulfate | 339 | $3,409 |
| Prasugrel Hcl | 48 | $3,223 |
| VascepaIcosapent Ethyl | 11 | $3,167 |
| Ranolazine ErRanolazine | 17 | $2,912 |
| Atorvastatin Calcium | 182 | $2,607 |
| Metoprolol Succinate | 53 | $1,063 |
| Rosuvastatin Calcium | 62 | $889 |
| Lisinopril | 74 | $721 |
| Carvedilol | 55 | $660 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 37 | $529 |
| Amlodipine Besylate | 47 | $512 |
| Ezetimibe | 23 | $384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $32,36333 claims |
| AstraZenecaBrilinta | $15 | $22,90030 claims |
| NovartisEntresto | $12 | $17,39715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Pensacola
- Rohit AminPensacola$560K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.